2022 JPAD Article

2022 Journal of Prevention of Alzheimer’s Disease:

 

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

File Type: 93
Categories: 2022
Tags: ACU193, INTERCEPT-AD, sabirnetug, Trial Design, TwentyTwentyTwo